Gilead Sciences/$GILD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Gilead Sciences
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Ticker
$GILD
Sector
Primary listing
Employees
17,000
Headquarters
Website
Gilead Sciences Metrics
BasicAdvanced
$162bn
17.77
$7.35
0.33
$3.19
2.51%
Price and volume
Market cap
$162bn
Beta
0.33
52-week high
$157.29
52-week low
$104.46
Average daily volume
5.8m
Dividend rate
$3.19
Financial strength
Current ratio
1.967
Quick ratio
1.536
Long term debt to equity
99.744
Total debt to equity
99.744
Dividend payout ratio (TTM)
54.72%
Interest coverage (TTM)
11.94%
Profitability
EBITDA (TTM)
14,738
Gross margin (TTM)
79.37%
Net profit margin (TTM)
30.99%
Operating margin (TTM)
40.30%
Effective tax rate (TTM)
14.09%
Revenue per employee (TTM)
$1,750,000
Management effectiveness
Return on assets (TTM)
13.29%
Return on equity (TTM)
43.36%
Valuation
Price to earnings (TTM)
17.774
Price to revenue (TTM)
5.463
Price to book
6.93
Price to tangible book (TTM)
-137.44
Price to free cash flow (TTM)
15.88
Free cash flow yield (TTM)
6.30%
Free cash flow per share (TTM)
8.23
Dividend yield (TTM)
2.44%
Forward dividend yield
2.51%
Growth
Revenue change (TTM)
3.48%
Earnings per share change (TTM)
55.43%
3-year revenue growth (CAGR)
3.21%
10-year revenue growth (CAGR)
-0.99%
3-year earnings per share growth (CAGR)
18.49%
10-year earnings per share growth (CAGR)
-4.55%
3-year dividend per share growth (CAGR)
2.76%
10-year dividend per share growth (CAGR)
6.37%
What the Analysts think about Gilead Sciences
Analyst ratings (Buy, Hold, Sell) for Gilead Sciences stock.
Gilead Sciences Financial Performance
Revenues and expenses
Gilead Sciences Earnings Performance
Company profitability
Gilead Sciences News
AllArticlesVideos
Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio
Business Wire·2 hours ago
Gilead Sciences and World Health Organization Expand Collaboration to Help Eliminate Visceral Leishmaniasis, a Fatal Parasitic Disease
Business Wire·8 hours ago
Gilead Sciences Leans on HIV Growth as Deals Build Oncology, Inflammation Pipeline
MarketBeat·4 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
FAQs